Panobinostat: all 136 studies that test it
Page 2 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid TumorsCompletedNCT01055795Phase 1
- Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's LymphomaTerminatedNCT01032148Phase 1
- A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host DiseaseWithdrawnNCT01028313Phase 2
- Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic FunctionCompletedNCT01007968Phase 1
- Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung CancersCompletedNCT01005797Phase 1
- Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal FunctionCompletedNCT00997399Phase 1
- ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast CancerWithdrawnNCT00993642Early Phase 1
- Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00962507Phase 1
- Carboplatin and Etoposide Plus LBH589 for Small Cell Lung CancerTerminatedNCT00958022Phase 1
- Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT00907179Phase 1
- Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell LymphomaCompletedNCT00901147Phase 2
- Panobinostat/Velcade in Multiple MyelomaTerminatedNCT00891033Phase 1
- Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid TumorsCompletedNCT00878904Phase 1
- Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by SurgeryTerminatedNCT00873002Phase 1
- Study of LBH589 (Panobinostat) to Treat Malignant Brain TumorsTerminatedNCT00848523Phase 2
- Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)CompletedNCT00840346Phase 1/2
- Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)TerminatedNCT00823290Phase 1
- A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast CancerCompletedNCT00788931Phase 1
- Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid TumorsCompletedNCT00739414Phase 1
- Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract CancersCompletedNCT00738751Phase 1
- Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/LymphomaTerminatedNCT00699296Phase 2
- Phase II Trial of LBH589 in Refractory Colorectal CancerCompletedNCT00690677Phase 2
- Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00686218Phase 1
- A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck CancerCompletedNCT00670553Phase 1
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate CancerCompletedNCT00663832Phase 1
- A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid TumorsCompletedNCT00570284Phase 1
- LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid TumorsCompletedNCT00556088Phase 1
- LBH589 and Gemcitabine in the Treatment of Solid TumorsTerminatedNCT00550199Phase 1
- Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural MesotheliomaCompletedNCT00535951Phase 1
- Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.CompletedNCT00532675Phase 1
- Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple MyelomaCompletedNCT00532389Phase 1
- A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid TumorsCompletedNCT00503451Phase 1
- Safety of LBH589 Alone and in Combination With IV Docetaxel and PrednisoneTerminatedNCT00493766Phase 1
- A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589CompletedNCT00472368Phase 1
- Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and PrednisoneTerminatedNCT00419536Phase 1
- LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell LymphomaCompletedNCT00412997Phase 1